Nath Bio-Genes (India) share news and announcements
NSE: NATHBIOGENBSE: 537291Agricultural Food & other ProductsSmall Cap
Last close ₹130.52up ₹0.15 (0.12%)BSE ₹127.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹130.37.
52-week range of traded prices to 23 Oct 2026
₹126.15Low, 30 Mar 2026₹204.00High, 30 Apr 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹248 Cr2,134th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 18 Sep 2026
- 6.8
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹7.21 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 8.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 4 May 2026
- 0.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 18 Sep 2026
- 5.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹7.21 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 4.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 18 Sep 2026
- 5.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 4 May 2026
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 8,55672.5% delivered
Nath Bio-Genes (India) share news and announcements
347 announcements, routine notices left out, newest first. Page 2 of 7.
Oct 2024
25 Oct · General Updates
25 Oct · General Updates
23 Oct · Management
23 Oct · Board meeting
Aug 2024
19 Aug · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.17 Aug · Updates
Jul 2024
23 Jul · Corporate action
May 2024
9 May · Updates
6 May · Analysts
Apr 2024
Mar 2024
12 Mar · Updates
Feb 2024
Jan 2024
18 Jan · Board meeting
Dec 2023
Oct 2023
14 Oct · Analysts
Aug 2023
Jul 2023
Jun 2023
May 2023